8-K: NRX Pharmaceuticals Changes Auditors Amid Going Concern Warning

NRX Pharmaceuticals, Inc. announced a change in its independent registered public accounting firm, dismissing Salberg & Company P.A. and engaging Weinberg & Company P.A.

Summary

• NRX Pharmaceuticals, Inc. (the Corporation) engaged Weinberg & Company P.A. as its new independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Audit Committee of the board of directors approved Weinberg's engagement on November 20, 2025.
• Weinberg had previously audited Dura Medical LLC, a company acquired by Hope Therapeutics, Inc., a subsidiary of NRx.
• Salberg & Company P.A. was dismissed as the independent registered public accounting firm on or around November 24, 2025.
• Salberg's audit reports for the fiscal years ended December 31, 2024, and December 31, 2023, included an explanatory paragraph regarding the Company's ability to continue as a going concern.
• There were no disagreements or reportable events between NRx Pharmaceuticals and Salberg during the two most recent fiscal years and subsequent interim period through September 30, 2025.
• NRx Pharmaceuticals did not consult Weinberg regarding accounting principles or audit opinions prior to their engagement.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the explicit mention of a 'going concern' explanatory paragraph in the previous auditor's reports, which signals significant financial uncertainty. While the auditor change itself is not inherently negative, the context provided by the outgoing auditor's report is a major concern.

Positives

• The company has secured a new independent registered public accounting firm, ensuring continuity in financial oversight.
• There were no reported disagreements or reportable events with the outgoing auditor, Salberg & Company P.A., regarding accounting principles or audit procedures.

Negatives

• The outgoing auditor, Salberg & Company P.A., included an explanatory paragraph in its audit reports for the fiscal years ended December 31, 2024, and December 31, 2023, concerning the Company's ability to continue as a going concern.

Risks

• The 'going concern' explanatory paragraph from the previous auditor indicates significant doubt about the company's ability to continue operations, which is a material risk to investors.
• A change in auditors, while sometimes routine, can raise questions about financial reporting stability, especially when coupled with a going concern warning.

Future Outlook

NA

Management Comments

• Jonathan Javitt, Interim Chief Executive Officer, signed the report on behalf of NRx Pharmaceuticals, Inc.

Industry Context

Changes in a company's independent registered public accounting firm are a routine part of corporate governance, often driven by factors such as cost, service quality, or M&A activity. However, such changes, especially when the outgoing auditor has issued a 'going concern' warning, can draw increased scrutiny from investors and regulators, potentially signaling underlying financial challenges. The engagement of an auditor previously associated with an acquired subsidiary (Dura Medical LLC) suggests a consolidation of auditing services.

Corporate Governance

Stakeholder Impact

• Shareholders: May face increased uncertainty regarding the company's financial stability due to the 'going concern' warning from the previous auditor. The change in auditors might also prompt questions about financial transparency.
• Investors: Will likely scrutinize future financial reports more closely for signs of improved financial health or continued challenges.
• Regulatory Authorities: The SEC will review the filing, particularly the disclosures related to the auditor change and the 'going concern' issue.

Next Steps

• Weinberg & Company P.A. will audit the Corporation's financial statements for the fiscal year ending December 31, 2025.

Key Dates

Recommendation

The explicit mention of a 'going concern' explanatory paragraph by the previous auditor for two consecutive fiscal years (2023 and 2024) is a severe red flag. This indicates substantial doubt about the company's ability to continue operations, which fundamentally undermines investor confidence and suggests significant financial distress. While the change in auditors itself is not a direct negative, the context provided by the outgoing auditor's report makes the stock highly speculative and risky. A seasoned investor would likely view this as a strong signal to exit or avoid the position until clear evidence of financial stability and resolution of the going concern issue emerges.

Keywords

NRX Pharmaceuticals, auditor change, Form 8-K, SEC filing, independent registered public accounting firm, going concern, corporate governance, financial reporting, Weinberg & Company P.A., Salberg & Company P.A.